APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neisseria meningitidis Infections Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neisseria meningitidis Infections Drug Market Analysis and Forecast 2026-2032

19 December 2025193 pages

Choose your research edition.

Industry ResearchNeisseria meningitidis Infections Drug Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Neisseria meningitidis Infections Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Neisseria meningitidis Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neisseria meningitidis Infections Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Neisseria meningitidis Infections Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Neisseria meningitidis Infections Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Neisseria meningitidis Infections Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neisseria meningitidis Infections Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neisseria meningitidis Infections Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neisseria meningitidis Infections Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Neisseria meningitidis Infections Drug include Biological E Ltd, Griffith University, ImmunoBiology Ltd, JN-International Medical Corp, MGB Biopharma Ltd, Panacea Biotec Ltd, Sanofi Pasteur SA, Serum Institute of India Ltd and Wellstat Vaccines LLC, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Neisseria meningitidis Infections Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neisseria meningitidis Infections Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Neisseria meningitidis Infections Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neisseria meningitidis Infections Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neisseria meningitidis Infections Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Neisseria meningitidis Infections Drug sales, projected growth trends, production technology, application and end-user industry.

Neisseria meningitidis Infections Drug Segment by Company

Biological E Ltd

Griffith University

ImmunoBiology Ltd

JN-International Medical Corp

MGB Biopharma Ltd

Panacea Biotec Ltd

Sanofi Pasteur SA

Serum Institute of India Ltd

Wellstat Vaccines LLC

Beijing Minhai Biotechnology Co Ltd

GlaxoSmithKline Plc

China National Pharmaceutical Group Corp

Pfizer Inc

Neisseria meningitidis Infections Drug Segment by Type

TP-10

NCL-195

MGBBP-3

Others

Neisseria meningitidis Infections Drug Segment by Application

Hospital

Clinic

Others

Neisseria meningitidis Infections Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neisseria meningitidis Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neisseria meningitidis Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neisseria meningitidis Infections Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Neisseria meningitidis Infections Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Neisseria meningitidis Infections Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neisseria meningitidis Infections Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neisseria meningitidis Infections Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. TP-10 Major Manufacturers Table 3. NCL-195 Major Manufacturers Table 4. MGBBP-3 Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global Neisseria meningitidis Infections Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Manufacturers Table 8. Clinic Major Manufacturers Table 9. Others Major Manufacturers Table 10. Neisseria meningitidis Infections Drug Industry Trends Table 11. Neisseria meningitidis Infections Drug Industry Drivers Table 12. Neisseria meningitidis Infections Drug Industry Opportunities and Challenges Table 13. Neisseria meningitidis Infections Drug Industry Restraints Table 14. Global Neisseria meningitidis Infections Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Neisseria meningitidis Infections Drug Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Neisseria meningitidis Infections Drug Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Neisseria meningitidis Infections Drug Revenue Market Share by Region (2021-2026) Table 18. Global Neisseria meningitidis Infections Drug Revenue Market Share by Region (2027-2032) Table 19. Global Neisseria meningitidis Infections Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 20. Global Neisseria meningitidis Infections Drug Sales by Region (2021-2026) & (W Units) Table 21. Global Neisseria meningitidis Infections Drug Sales by Region (2027-2032) & (W Units) Table 22. Global Neisseria meningitidis Infections Drug Sales Market Share by Region (2021-2026) Table 23. Global Neisseria meningitidis Infections Drug Sales Market Share by Region (2027-2032) Table 24. Global Neisseria meningitidis Infections Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Neisseria meningitidis Infections Drug Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Neisseria meningitidis Infections Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Neisseria meningitidis Infections Drug Sales Market Share by Manufacturers (2021-2026) Table 28. Global Neisseria meningitidis Infections Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Neisseria meningitidis Infections Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Neisseria meningitidis Infections Drug Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Neisseria meningitidis Infections Drug Manufacturers, Product Type & Application Table 32. Global Neisseria meningitidis Infections Drug Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Neisseria meningitidis Infections Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Neisseria meningitidis Infections Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Neisseria meningitidis Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Neisseria meningitidis Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Neisseria meningitidis Infections Drug Revenue Market Share by Type (2021-2026) Table 39. Global Neisseria meningitidis Infections Drug Revenue Market Share by Type (2027-2032) Table 40. Global Neisseria meningitidis Infections Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 41. Global Neisseria meningitidis Infections Drug Sales by Type (2021-2026) & (W Units) Table 42. Global Neisseria meningitidis Infections Drug Sales by Type (2027-2032) & (W Units) Table 43. Global Neisseria meningitidis Infections Drug Sales Market Share by Type (2021-2026) Table 44. Global Neisseria meningitidis Infections Drug Sales Market Share by Type (2027-2032) Table 45. Global Neisseria meningitidis Infections Drug Price by Type (2021-2026) & (US$/Unit) Table 46. Global Neisseria meningitidis Infections Drug Price by Type (2027-2032) & (US$/Unit) Table 47. Global Neisseria meningitidis Infections Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Neisseria meningitidis Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Neisseria meningitidis Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Neisseria meningitidis Infections Drug Revenue Market Share by Application (2021-2026) Table 51. Global Neisseria meningitidis Infections Drug Revenue Market Share by Application (2027-2032) Table 52. Global Neisseria meningitidis Infections Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 53. Global Neisseria meningitidis Infections Drug Sales by Application (2021-2026) & (W Units) Table 54. Global Neisseria meningitidis Infections Drug Sales by Application (2027-2032) & (W Units) Table 55. Global Neisseria meningitidis Infections Drug Sales Market Share by Application (2021-2026) Table 56. Global Neisseria meningitidis Infections Drug Sales Market Share by Application (2027-2032) Table 57. Global Neisseria meningitidis Infections Drug Price by Application (2021-2026) & (US$/Unit) Table 58. Global Neisseria meningitidis Infections Drug Price by Application (2027-2032) & (US$/Unit) Table 59. Biological E Ltd Company Information Table 60. Biological E Ltd Business Overview Table 61. Biological E Ltd Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Biological E Ltd Neisseria meningitidis Infections Drug Product Portfolio Table 63. Biological E Ltd Recent Development Table 64. Griffith University Company Information Table 65. Griffith University Business Overview Table 66. Griffith University Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Griffith University Neisseria meningitidis Infections Drug Product Portfolio Table 68. Griffith University Recent Development Table 69. ImmunoBiology Ltd Company Information Table 70. ImmunoBiology Ltd Business Overview Table 71. ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. ImmunoBiology Ltd Neisseria meningitidis Infections Drug Product Portfolio Table 73. ImmunoBiology Ltd Recent Development Table 74. JN-International Medical Corp Company Information Table 75. JN-International Medical Corp Business Overview Table 76. JN-International Medical Corp Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. JN-International Medical Corp Neisseria meningitidis Infections Drug Product Portfolio Table 78. JN-International Medical Corp Recent Development Table 79. MGB Biopharma Ltd Company Information Table 80. MGB Biopharma Ltd Business Overview Table 81. MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. MGB Biopharma Ltd Neisseria meningitidis Infections Drug Product Portfolio Table 83. MGB Biopharma Ltd Recent Development Table 84. Panacea Biotec Ltd Company Information Table 85. Panacea Biotec Ltd Business Overview Table 86. Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Panacea Biotec Ltd Neisseria meningitidis Infections Drug Product Portfolio Table 88. Panacea Biotec Ltd Recent Development Table 89. Sanofi Pasteur SA Company Information Table 90. Sanofi Pasteur SA Business Overview Table 91. Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Sanofi Pasteur SA Neisseria meningitidis Infections Drug Product Portfolio Table 93. Sanofi Pasteur SA Recent Development Table 94. Serum Institute of India Ltd Company Information Table 95. Serum Institute of India Ltd Business Overview Table 96. Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Serum Institute of India Ltd Neisseria meningitidis Infections Drug Product Portfolio Table 98. Serum Institute of India Ltd Recent Development Table 99. Wellstat Vaccines LLC Company Information Table 100. Wellstat Vaccines LLC Business Overview Table 101. Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Product Portfolio Table 103. Wellstat Vaccines LLC Recent Development Table 104. Beijing Minhai Biotechnology Co Ltd Company Information Table 105. Beijing Minhai Biotechnology Co Ltd Business Overview Table 106. Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Product Portfolio Table 108. Beijing Minhai Biotechnology Co Ltd Recent Development Table 109. GlaxoSmithKline Plc Company Information Table 110. GlaxoSmithKline Plc Business Overview Table 111. GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Product Portfolio Table 113. GlaxoSmithKline Plc Recent Development Table 114. China National Pharmaceutical Group Corp Company Information Table 115. China National Pharmaceutical Group Corp Business Overview Table 116. China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Product Portfolio Table 118. China National Pharmaceutical Group Corp Recent Development Table 119. Pfizer Inc Company Information Table 120. Pfizer Inc Business Overview Table 121. Pfizer Inc Neisseria meningitidis Infections Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Pfizer Inc Neisseria meningitidis Infections Drug Product Portfolio Table 123. Pfizer Inc Recent Development Table 124. North America Neisseria meningitidis Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 125. North America Neisseria meningitidis Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 126. North America Neisseria meningitidis Infections Drug Sales by Type (2021-2026) & (W Units) Table 127. North America Neisseria meningitidis Infections Drug Sales by Type (2027-2032) & (W Units) Table 128. North America Neisseria meningitidis Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 129. North America Neisseria meningitidis Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 130. North America Neisseria meningitidis Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 131. North America Neisseria meningitidis Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 132. North America Neisseria meningitidis Infections Drug Sales by Application (2021-2026) & (W Units) Table 133. North America Neisseria meningitidis Infections Drug Sales by Application (2027-2032) & (W Units) Table 134. North America Neisseria meningitidis Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 135. North America Neisseria meningitidis Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 136. North America Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. North America Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 138. North America Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 139. North America Neisseria meningitidis Infections Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 140. North America Neisseria meningitidis Infections Drug Sales by Country (2021-2026) & (W Units) Table 141. North America Neisseria meningitidis Infections Drug Sales by Country (2027-2032) & (W Units) Table 142. North America Neisseria meningitidis Infections Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 143. North America Neisseria meningitidis Infections Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 144. United States Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 145. Canada Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 146. Europe Neisseria meningitidis Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 147. Europe Neisseria meningitidis Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 148. Europe Neisseria meningitidis Infections Drug Sales by Type (2021-2026) & (W Units) Table 149. Europe Neisseria meningitidis Infections Drug Sales by Type (2027-2032) & (W Units) Table 150. Europe Neisseria meningitidis Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 151. Europe Neisseria meningitidis Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 152. Europe Neisseria meningitidis Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 153. Europe Neisseria meningitidis Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 154. Europe Neisseria meningitidis Infections Drug Sales by Application (2021-2026) & (W Units) Table 155. Europe Neisseria meningitidis Infections Drug Sales by Application (2027-2032) & (W Units) Table 156. Europe Neisseria meningitidis Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 157. Europe Neisseria meningitidis Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 158. Europe Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. Europe Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 160. Europe Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 161. Europe Neisseria meningitidis Infections Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 162. Europe Neisseria meningitidis Infections Drug Sales by Country (2021-2026) & (W Units) Table 163. Europe Neisseria meningitidis Infections Drug Sales by Country (2027-2032) & (W Units) Table 164. Europe Neisseria meningitidis Infections Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 165. Europe Neisseria meningitidis Infections Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 166. Germany Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 167. France Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 168. U.K. Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 169. Italy Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 170. Netherlands Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 171. Nordic Countries Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 172. China Neisseria meningitidis Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 173. China Neisseria meningitidis Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 174. China Neisseria meningitidis Infections Drug Sales by Type (2021-2026) & (W Units) Table 175. China Neisseria meningitidis Infections Drug Sales by Type (2027-2032) & (W Units) Table 176. China Neisseria meningitidis Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 177. China Neisseria meningitidis Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 178. China Neisseria meningitidis Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 179. China Neisseria meningitidis Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 180. China Neisseria meningitidis Infections Drug Sales by Application (2021-2026) & (W Units) Table 181. China Neisseria meningitidis Infections Drug Sales by Application (2027-2032) & (W Units) Table 182. China Neisseria meningitidis Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 183. China Neisseria meningitidis Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 184. Asia Neisseria meningitidis Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 185. Asia Neisseria meningitidis Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 186. Asia Neisseria meningitidis Infections Drug Sales by Type (2021-2026) & (W Units) Table 187. Asia Neisseria meningitidis Infections Drug Sales by Type (2027-2032) & (W Units) Table 188. Asia Neisseria meningitidis Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 189. Asia Neisseria meningitidis Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 190. Asia Neisseria meningitidis Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 191. Asia Neisseria meningitidis Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 192. Asia Neisseria meningitidis Infections Drug Sales by Application (2021-2026) & (W Units) Table 193. Asia Neisseria meningitidis Infections Drug Sales by Application (2027-2032) & (W Units) Table 194. Asia Neisseria meningitidis Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 195. Asia Neisseria meningitidis Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 196. Asia Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 197. Asia Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 198. Asia Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 199. Asia Neisseria meningitidis Infections Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 200. Asia Neisseria meningitidis Infections Drug Sales by Country (2021-2026) & (W Units) Table 201. Asia Neisseria meningitidis Infections Drug Sales by Country (2027-2032) & (W Units) Table 202. Asia Neisseria meningitidis Infections Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 203. Asia Neisseria meningitidis Infections Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 204. Japan Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 205. South Korea Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 206. India Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 207. Australia Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 208. China Taiwan Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 209. Southeast Asia Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 210. SAMEA Neisseria meningitidis Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 211. SAMEA Neisseria meningitidis Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 212. SAMEA Neisseria meningitidis Infections Drug Sales by Type (2021-2026) & (W Units) Table 213. SAMEA Neisseria meningitidis Infections Drug Sales by Type (2027-2032) & (W Units) Table 214. SAMEA Neisseria meningitidis Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 215. SAMEA Neisseria meningitidis Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 216. SAMEA Neisseria meningitidis Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 217. SAMEA Neisseria meningitidis Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 218. SAMEA Neisseria meningitidis Infections Drug Sales by Application (2021-2026) & (W Units) Table 219. SAMEA Neisseria meningitidis Infections Drug Sales by Application (2027-2032) & (W Units) Table 220. SAMEA Neisseria meningitidis Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 221. SAMEA Neisseria meningitidis Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 222. SAMEA Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 223. SAMEA Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 224. SAMEA Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 225. SAMEA Neisseria meningitidis Infections Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 226. SAMEA Neisseria meningitidis Infections Drug Sales by Country (2021-2026) & (W Units) Table 227. SAMEA Neisseria meningitidis Infections Drug Sales by Country (2027-2032) & (W Units) Table 228. SAMEA Neisseria meningitidis Infections Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 229. SAMEA Neisseria meningitidis Infections Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 230. Brazil Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 231. Argentina Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 232. Chile Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 233. Colombia Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 234. Peru Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 235. Saudi Arabia Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 236. Israel Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 237. UAE Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 238. Turkey Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 239. Iran Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 240. Egypt Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Table 241. Key Raw Materials Table 242. Raw Materials Key Suppliers Table 243. Neisseria meningitidis Infections Drug Distributors List Table 244. Neisseria meningitidis Infections Drug Customers List Table 245. Research Programs/Design for This Report Table 246. Authors List of This Report Table 247. Secondary Sources Table 248. Primary Sources List of Figures Figure 1. Neisseria meningitidis Infections Drug Image Figure 2. Global Neisseria meningitidis Infections Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neisseria meningitidis Infections Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. TP-10 Image Figure 5. NCL-195 Image Figure 6. MGBBP-3 Image Figure 7. Others Image Figure 8. Global Neisseria meningitidis Infections Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Neisseria meningitidis Infections Drug Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Others Image Figure 13. Global Neisseria meningitidis Infections Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Neisseria meningitidis Infections Drug Revenue (2021-2032) & (US$ Million) Figure 15. Global Neisseria meningitidis Infections Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Neisseria meningitidis Infections Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Neisseria meningitidis Infections Drug Revenue Market Share by Region (2021-2032) Figure 18. Global Neisseria meningitidis Infections Drug Sales (2021-2032) & (W Units) Figure 19. Global Neisseria meningitidis Infections Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 20. Global Neisseria meningitidis Infections Drug Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Neisseria meningitidis Infections Drug Sales YoY (2021-2032) & (W Units) Figure 22. Europe Neisseria meningitidis Infections Drug Sales YoY (2021-2032) & (W Units) Figure 23. China Neisseria meningitidis Infections Drug Sales YoY (2021-2032) & (W Units) Figure 24. Asia (Excluding China) Neisseria meningitidis Infections Drug Sales YoY (2021-2032) & (W Units) Figure 25. South America, Middle East and Africa Neisseria meningitidis Infections Drug Sales YoY (2021-2032) & (W Units) Figure 26. Global Neisseria meningitidis Infections Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Neisseria meningitidis Infections Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Neisseria meningitidis Infections Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Neisseria meningitidis Infections Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Neisseria meningitidis Infections Drug Revenue Market Share by Type (2021-2032) Figure 32. Global Neisseria meningitidis Infections Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 33. Global Neisseria meningitidis Infections Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Neisseria meningitidis Infections Drug Sales Market Share by Type (2021-2032) Figure 35. Global Neisseria meningitidis Infections Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Neisseria meningitidis Infections Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Neisseria meningitidis Infections Drug Revenue Market Share by Application (2021-2032) Figure 38. Global Neisseria meningitidis Infections Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 39. Global Neisseria meningitidis Infections Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Neisseria meningitidis Infections Drug Sales Market Share by Application (2021-2032) Figure 41. North America Neisseria meningitidis Infections Drug Revenue Share by Type (2021-2032) Figure 42. North America Neisseria meningitidis Infections Drug Sales Share by Type (2021-2032) Figure 43. North America Neisseria meningitidis Infections Drug Revenue Share by Application (2021-2032) Figure 44. North America Neisseria meningitidis Infections Drug Sales Share by Application (2021-2032) Figure 45. North America Neisseria meningitidis Infections Drug Revenue Share by Country (2021-2032) Figure 46. North America Neisseria meningitidis Infections Drug Sales Share by Country (2021-2032) Figure 47. Europe Neisseria meningitidis Infections Drug Revenue Share by Type (2021-2032) Figure 48. Europe Neisseria meningitidis Infections Drug Sales Share by Type (2021-2032) Figure 49. Europe Neisseria meningitidis Infections Drug Revenue Share by Application (2021-2032) Figure 50. Europe Neisseria meningitidis Infections Drug Sales Share by Application (2021-2032) Figure 51. Europe Neisseria meningitidis Infections Drug Revenue Share by Country (2021-2032) Figure 52. Europe Neisseria meningitidis Infections Drug Sales Share by Country (2021-2032) Figure 53. China Neisseria meningitidis Infections Drug Revenue Share by Type (2021-2032) Figure 54. China Neisseria meningitidis Infections Drug Sales Share by Type (2021-2032) Figure 55. China Neisseria meningitidis Infections Drug Revenue Share by Application (2021-2032) Figure 56. China Neisseria meningitidis Infections Drug Sales Share by Application (2021-2032) Figure 57. Asia Neisseria meningitidis Infections Drug Revenue Share by Type (2021-2032) Figure 58. Asia Neisseria meningitidis Infections Drug Sales Share by Type (2021-2032) Figure 59. Asia Neisseria meningitidis Infections Drug Revenue Share by Application (2021-2032) Figure 60. Asia Neisseria meningitidis Infections Drug Sales Share by Application (2021-2032) Figure 61. Asia Neisseria meningitidis Infections Drug Revenue Share by Country (2021-2032) Figure 62. Asia Neisseria meningitidis Infections Drug Sales Share by Country (2021-2032) Figure 63. SAMEA Neisseria meningitidis Infections Drug Revenue Share by Type (2021-2032) Figure 64. SAMEA Neisseria meningitidis Infections Drug Sales Share by Type (2021-2032) Figure 65. SAMEA Neisseria meningitidis Infections Drug Revenue Share by Application (2021-2032) Figure 66. SAMEA Neisseria meningitidis Infections Drug Sales Share by Application (2021-2032) Figure 67. SAMEA Neisseria meningitidis Infections Drug Revenue Share by Country (2021-2032) Figure 68. SAMEA Neisseria meningitidis Infections Drug Sales Share by Country (2021-2032) Figure 69. Neisseria meningitidis Infections Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Neisseria meningitidis Infections Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • TP-10
  • NCL-195
  • MGBBP-3
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Biological E Ltd
  • Griffith University
  • ImmunoBiology Ltd
  • JN-International Medical Corp
  • MGB Biopharma Ltd
  • Panacea Biotec Ltd
  • Sanofi Pasteur SA
  • Serum Institute of India Ltd
  • Wellstat Vaccines LLC
  • Beijing Minhai Biotechnology Co Ltd
  • GlaxoSmithKline Plc
  • China National Pharmaceutical Group Corp
  • Pfizer Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neisseria meningitidis Infections Drug Market by Type
  3. 1.2.1 Global Neisseria meningitidis Infections Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 TP-10
  5. 1.2.3 NCL-195
  6. 1.2.4 MGBBP-3
  7. 1.2.5 Others
  8. 1.3 Neisseria meningitidis Infections Drug Market by Application
  9. 1.3.1 Global Neisseria meningitidis Infections Drug Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Neisseria meningitidis Infections Drug Market Dynamics
  1. 2.1 Neisseria meningitidis Infections Drug Industry Trends
  2. 2.2 Neisseria meningitidis Infections Drug Industry Drivers
  3. 2.3 Neisseria meningitidis Infections Drug Industry Opportunities and Challenges
  4. 2.4 Neisseria meningitidis Infections Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Neisseria meningitidis Infections Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Neisseria meningitidis Infections Drug Revenue by Region
  3. 3.2.1 Global Neisseria meningitidis Infections Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neisseria meningitidis Infections Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Neisseria meningitidis Infections Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Neisseria meningitidis Infections Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Neisseria meningitidis Infections Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Neisseria meningitidis Infections Drug Sales by Region
  9. 3.4.1 Global Neisseria meningitidis Infections Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Neisseria meningitidis Infections Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Neisseria meningitidis Infections Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Neisseria meningitidis Infections Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Neisseria meningitidis Infections Drug Revenue by Manufacturers
  2. 4.1.1 Global Neisseria meningitidis Infections Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Neisseria meningitidis Infections Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Neisseria meningitidis Infections Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neisseria meningitidis Infections Drug Sales by Manufacturers
  6. 4.2.1 Global Neisseria meningitidis Infections Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Neisseria meningitidis Infections Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Neisseria meningitidis Infections Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Neisseria meningitidis Infections Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Neisseria meningitidis Infections Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Neisseria meningitidis Infections Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Neisseria meningitidis Infections Drug Manufacturers, Product Type & Application
  13. 4.7 Global Neisseria meningitidis Infections Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Neisseria meningitidis Infections Drug Market CR5 and HHI
  16. 4.8.2 2025 Neisseria meningitidis Infections Drug Tier 1, Tier 2, and Tier 3
5 Neisseria meningitidis Infections Drug Market by Type
  1. 5.1 Global Neisseria meningitidis Infections Drug Revenue by Type
  2. 5.1.1 Global Neisseria meningitidis Infections Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Neisseria meningitidis Infections Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Neisseria meningitidis Infections Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Neisseria meningitidis Infections Drug Sales by Type
  6. 5.2.1 Global Neisseria meningitidis Infections Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neisseria meningitidis Infections Drug Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Neisseria meningitidis Infections Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Neisseria meningitidis Infections Drug Price by Type
6 Neisseria meningitidis Infections Drug Market by Application
  1. 6.1 Global Neisseria meningitidis Infections Drug Revenue by Application
  2. 6.1.1 Global Neisseria meningitidis Infections Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Neisseria meningitidis Infections Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Neisseria meningitidis Infections Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Neisseria meningitidis Infections Drug Sales by Application
  6. 6.2.1 Global Neisseria meningitidis Infections Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Neisseria meningitidis Infections Drug Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Neisseria meningitidis Infections Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Neisseria meningitidis Infections Drug Price by Application
7 Company Profiles
  1. 7.1 Biological E Ltd
  2. 7.1.1 Biological E Ltd Company Information
  3. 7.1.2 Biological E Ltd Business Overview
  4. 7.1.3 Biological E Ltd Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Biological E Ltd Neisseria meningitidis Infections Drug Product Portfolio
  6. 7.1.5 Biological E Ltd Recent Developments
  7. 7.2 Griffith University
  8. 7.2.1 Griffith University Company Information
  9. 7.2.2 Griffith University Business Overview
  10. 7.2.3 Griffith University Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Griffith University Neisseria meningitidis Infections Drug Product Portfolio
  12. 7.2.5 Griffith University Recent Developments
  13. 7.3 ImmunoBiology Ltd
  14. 7.3.1 ImmunoBiology Ltd Company Information
  15. 7.3.2 ImmunoBiology Ltd Business Overview
  16. 7.3.3 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Product Portfolio
  18. 7.3.5 ImmunoBiology Ltd Recent Developments
  19. 7.4 JN-International Medical Corp
  20. 7.4.1 JN-International Medical Corp Company Information
  21. 7.4.2 JN-International Medical Corp Business Overview
  22. 7.4.3 JN-International Medical Corp Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 JN-International Medical Corp Neisseria meningitidis Infections Drug Product Portfolio
  24. 7.4.5 JN-International Medical Corp Recent Developments
  25. 7.5 MGB Biopharma Ltd
  26. 7.5.1 MGB Biopharma Ltd Company Information
  27. 7.5.2 MGB Biopharma Ltd Business Overview
  28. 7.5.3 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Product Portfolio
  30. 7.5.5 MGB Biopharma Ltd Recent Developments
  31. 7.6 Panacea Biotec Ltd
  32. 7.6.1 Panacea Biotec Ltd Company Information
  33. 7.6.2 Panacea Biotec Ltd Business Overview
  34. 7.6.3 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Product Portfolio
  36. 7.6.5 Panacea Biotec Ltd Recent Developments
  37. 7.7 Sanofi Pasteur SA
  38. 7.7.1 Sanofi Pasteur SA Company Information
  39. 7.7.2 Sanofi Pasteur SA Business Overview
  40. 7.7.3 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Product Portfolio
  42. 7.7.5 Sanofi Pasteur SA Recent Developments
  43. 7.8 Serum Institute of India Ltd
  44. 7.8.1 Serum Institute of India Ltd Company Information
  45. 7.8.2 Serum Institute of India Ltd Business Overview
  46. 7.8.3 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Product Portfolio
  48. 7.8.5 Serum Institute of India Ltd Recent Developments
  49. 7.9 Wellstat Vaccines LLC
  50. 7.9.1 Wellstat Vaccines LLC Company Information
  51. 7.9.2 Wellstat Vaccines LLC Business Overview
  52. 7.9.3 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Product Portfolio
  54. 7.9.5 Wellstat Vaccines LLC Recent Developments
  55. 7.10 Beijing Minhai Biotechnology Co Ltd
  56. 7.10.1 Beijing Minhai Biotechnology Co Ltd Company Information
  57. 7.10.2 Beijing Minhai Biotechnology Co Ltd Business Overview
  58. 7.10.3 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Product Portfolio
  60. 7.10.5 Beijing Minhai Biotechnology Co Ltd Recent Developments
  61. 7.11 GlaxoSmithKline Plc
  62. 7.11.1 GlaxoSmithKline Plc Company Information
  63. 7.11.2 GlaxoSmithKline Plc Business Overview
  64. 7.11.3 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Product Portfolio
  66. 7.11.5 GlaxoSmithKline Plc Recent Developments
  67. 7.12 China National Pharmaceutical Group Corp
  68. 7.12.1 China National Pharmaceutical Group Corp Company Information
  69. 7.12.2 China National Pharmaceutical Group Corp Business Overview
  70. 7.12.3 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Product Portfolio
  72. 7.12.5 China National Pharmaceutical Group Corp Recent Developments
  73. 7.13 Pfizer Inc
  74. 7.13.1 Pfizer Inc Company Information
  75. 7.13.2 Pfizer Inc Business Overview
  76. 7.13.3 Pfizer Inc Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Pfizer Inc Neisseria meningitidis Infections Drug Product Portfolio
  78. 7.13.5 Pfizer Inc Recent Developments
8 North America
  1. 8.1 North America Neisseria meningitidis Infections Drug Market Size by Type
  2. 8.1.1 North America Neisseria meningitidis Infections Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Neisseria meningitidis Infections Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Neisseria meningitidis Infections Drug Price by Type (2021-2032)
  5. 8.2 North America Neisseria meningitidis Infections Drug Market Size by Application
  6. 8.2.1 North America Neisseria meningitidis Infections Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Neisseria meningitidis Infections Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Neisseria meningitidis Infections Drug Price by Application (2021-2032)
  9. 8.3 North America Neisseria meningitidis Infections Drug Market Size by Country
  10. 8.3.1 North America Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Neisseria meningitidis Infections Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Neisseria meningitidis Infections Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Neisseria meningitidis Infections Drug Market Size by Type
  2. 9.1.1 Europe Neisseria meningitidis Infections Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Neisseria meningitidis Infections Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Neisseria meningitidis Infections Drug Price by Type (2021-2032)
  5. 9.2 Europe Neisseria meningitidis Infections Drug Market Size by Application
  6. 9.2.1 Europe Neisseria meningitidis Infections Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Neisseria meningitidis Infections Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Neisseria meningitidis Infections Drug Price by Application (2021-2032)
  9. 9.3 Europe Neisseria meningitidis Infections Drug Market Size by Country
  10. 9.3.1 Europe Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Neisseria meningitidis Infections Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Neisseria meningitidis Infections Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Neisseria meningitidis Infections Drug Market Size by Type
  2. 10.1.1 China Neisseria meningitidis Infections Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Neisseria meningitidis Infections Drug Sales by Type (2021-2032)
  4. 10.1.3 China Neisseria meningitidis Infections Drug Price by Type (2021-2032)
  5. 10.2 China Neisseria meningitidis Infections Drug Market Size by Application
  6. 10.2.1 China Neisseria meningitidis Infections Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Neisseria meningitidis Infections Drug Sales by Application (2021-2032)
  8. 10.2.3 China Neisseria meningitidis Infections Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neisseria meningitidis Infections Drug Market Size by Type
  2. 11.1.1 Asia Neisseria meningitidis Infections Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Neisseria meningitidis Infections Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Neisseria meningitidis Infections Drug Price by Type (2021-2032)
  5. 11.2 Asia Neisseria meningitidis Infections Drug Market Size by Application
  6. 11.2.1 Asia Neisseria meningitidis Infections Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Neisseria meningitidis Infections Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Neisseria meningitidis Infections Drug Price by Application (2021-2032)
  9. 11.3 Asia Neisseria meningitidis Infections Drug Market Size by Country
  10. 11.3.1 Asia Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Neisseria meningitidis Infections Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Neisseria meningitidis Infections Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neisseria meningitidis Infections Drug Market Size by Type
  2. 12.1.1 SAMEA Neisseria meningitidis Infections Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Neisseria meningitidis Infections Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Neisseria meningitidis Infections Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Neisseria meningitidis Infections Drug Market Size by Application
  6. 12.2.1 SAMEA Neisseria meningitidis Infections Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Neisseria meningitidis Infections Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Neisseria meningitidis Infections Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Neisseria meningitidis Infections Drug Market Size by Country
  10. 12.3.1 SAMEA Neisseria meningitidis Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Neisseria meningitidis Infections Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Neisseria meningitidis Infections Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Neisseria meningitidis Infections Drug Value Chain Analysis
  2. 13.1.1 Neisseria meningitidis Infections Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Neisseria meningitidis Infections Drug Production Mode & Process
  6. 13.2 Neisseria meningitidis Infections Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Neisseria meningitidis Infections Drug Distributors
  9. 13.2.3 Neisseria meningitidis Infections Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst